Pharmacogenomics in the treatment of mood disorders: Strategies and Opportunities for personalized psychiatry

EPMA Journal

Volumn 8, Issue 3, 2017, Pages 211-227

  Amare, Azmeraw T ^a   Schubert, Klaus Oliver ^a,b   Baune, Bernhard T ^a  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b Mental Health Services   (Australia)

Author keywords

Bipolar disorder; Depression; Lithium; Personalized psychiatry; Pharmacogenomics; Predictive preventive and personalized medicine (PPPM); SSRIs

Indexed keywords

AMFEBUTAMONE; CITALOPRAM; CLOMIPRAMINE; ESCITALOPRAM; FLUOXETINE; LITHIUM SALT; NEFAZODONE; NORTRIPTYLINE; PAROXETINE; REBOXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; VENLAFAXINE;

ALGORITHM; BIPOLAR DISORDER; DRUG EFFICACY; DRUG INDUSTRY; DRUG RESPONSE; EPIGENETICS; GENE PRODUCT; GENETIC SCREENING; GENOMICS; HEALTH CARE COST; HUMAN; MAJOR DEPRESSION; METABOLOMICS; MICROBIOME; MOOD DISORDER; PATIENT CARE; PATIENT SAFETY; PERSONALIZED MEDICINE; PERSONALIZED PSYCHIATRY; PHARMACOGENOMICS; PRIORITY JOURNAL; PROGNOSIS; PROTEOMICS; REVIEW; SEXUAL DYSFUNCTION; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 85029625040     PISSN: 18785077     EISSN: 18785085     Source Type: Journal    
DOI: 10.1007/s13167-017-0112-8     Document Type: Review

References (121)

1. Aas M, Henry C, Andreassen OA, et al. The role of childhood trauma in bipolar disorders. Int J Bipolar Disord. 2016;4:2.
2. Adkins DE, Clark SL, Aberg K, et al. Genome-wide pharmacogenomic study of citalopram-induced side effects in STAR*D. Transl Psychiatry. 2012;2:e129.
3. Amare AT, Schubert KO, Klingler-Hoffmann M, et al. The genetic overlap between mood disorders and cardiometabolic diseases: a systematic review of genome wide and candidate gene studies. Transl Psychiatry. 2017;7:e1007.
4. Andrade L, Caraveo-Anduaga JJ, Berglund P, et al. The epidemiology of major depressive episodes: results from the International Consortium of Psychiatric Epidemiology (ICPE) surveys. Int J Methods Psychiatr Res. 2003;12:3–21.
5. American Psychiatric Association, DSM-5 Task Force. Diagnostic and statistical manual of mental disorders: DSM-5. Arlington: American Psychiatric Association; 2013.
6. Baffa A, Hohoff C, Baune BT, et al. Norepinephrine and serotonin transporter genes: impact on treatment response in depression. Neuropsychobiology. 2010;62:121–31.
7. Baune BT, Dannlowski U, Domschke K, et al. The interleukin 1 beta (IL1B) gene is associated with failure to achieve remission and impaired emotion processing in major depression. Biol Psychiatry. 2010;67:543–9.
8. Baune BT, Hohoff C, Berger K, et al. Association of the COMT val158met variant with antidepressant treatment response in major depression. Neuropsychopharmacology. 2008;33:924–32.
9. Baune BT, Hohoff C, Mortensen LS, et al. Serotonin transporter polymorphism (5-HTTLPR) association with melancholic depression: a female specific effect? Depress Anxiety. 2008;25:920–5.
10. Biernacka JM, Sangkuhl K, Jenkins G, et al. The International SSRI Pharmacogenomics Consortium (ISPC): a genome-wide association study of antidepressant treatment response. Transl Psychiatry. 2015;5:e553.
11. Bondolfi G, Aubry JM, Golaz J, et al. A stepwise drug treatment algorithm to obtain complete remission in depression: a Geneva study. Swiss Med Wkly. 2006;136:78–85.
12. Breitenstein B, Scheuer S, Pfister H, et al. The clinical application of ABCB1 genotyping in antidepressant treatment: a pilot study. CNS Spectr. 2014;19:165–75.
13. Breitfeld J, Scholl C, Steffens M, et al. Gene expression and proliferation biomarkers for antidepressant treatment resistance. Transl Psychiatry. 2017;7:e1061.
14. Cade JF. Lithium salts in the treatment of psychotic excitement. Med J Aust. 1949;2:349–52.
15. Chekroud AM, Zotti RJ, Shehzad Z, et al. Cross-trial prediction of treatment outcome in depression: a machine learning approach. The Lancet Psychiatry. 2016;3:243–50.
16. Chen CH, Lee CS, Lee MT, et al. Variant GADL1 and response to lithium therapy in bipolar I disorder. N Engl J Med. 2014;370:119–28.
17. Civelek M, Lusis AJ. Systems genetics approaches to understand complex traits. Nat Rev Genet. 2014;15:34–48.
18. Clark SL, Adkins DE, Aberg K, et al. Pharmacogenomic study of side-effects for antidepressant treatment options in STAR*D. Psychol Med. 2012;42:1151–62.
19. Clayton AH, Croft HA, Horrigan JP, et al. Bupropion extended release compared with escitalopram: effects on sexual functioning and antidepressant efficacy in 2 randomized, double-blind, placebo-controlled studies. J Clin Psychiatry. 2006;67:736–46.
20. Consortium C. Sparse whole-genome sequencing identifies two loci for major depressive disorder. Nature. 2015;523:588.
21. Cross-Disorder Group of the Psychiatric Genomics C. Genetic relationship between five psychiatric disorders estimated from genome-wide SNPs. Nat Genet. 2013;45:984–94.
22. Cross-Disorder Group of the Psychiatric Genomics C. Identification of risk loci with shared effects on five major psychiatric disorders: a genome-wide analysis. Lancet. 2013;381:1371-9.
23. Deans E. Microbiome and mental health in the modern environment. J Physiol Anthropol. 2017;36:1.
24. Direk N, Williams S, Smith JA, et al. An analysis of two genome-wide association meta-analyses identifies a new locus for broad depression phenotype. Biol Psychiatry. 2017;82:322-29.
25. Doherty JL, Owen MJ. Genomic insights into the overlap between psychiatric disorders: implications for research and clinical practice. Genome Med. 2014;6:29–9.
26. Domschke K, Dannlowski U, Ohrmann P, et al. Cannabinoid receptor 1 (CNR1) gene: impact on antidepressant treatment response and emotion processing in major depression. Eur Neuropsychopharmacol. 2008;18:751-9.
27. Domschke K, Hohoff C, Mortensen LS, et al. Monoamine oxidase a variant influences antidepressant treatment response in female patients with major depression. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32:224–8.
28. Domschke K, Tidow N, Schwarte K, et al. Serotonin transporter gene hypomethylation predicts impaired antidepressant treatment response. Int J Neuropsychopharmacol. 2014;17:1167–76.
29. Dusi N, Barlati S, Vita A, et al. Brain structural effects of antidepressant treatment in major depression. Curr Neuropharmacol. 2015;13:458–65.
30. Fabbri C, Di Girolamo G, Serretti A. Pharmacogenetics of antidepressant drugs: an update after almost 20 years of research. Am J Med Genet B Neuropsychiatr Genet. 2013;162B:487–520.
31. Fabbri C, Serretti A. Pharmacogenetics of major depressive disorder: top genes and pathways toward clinical applications. Curr Psychiatry Rep. 2015;17:50.
32. Fava M, Rush AJ, Trivedi MH, et al. Background and rationale for the sequenced treatment alternatives to relieve depression (STAR*D) study. Psychiatr Clin North Am. 2003;26:457–494, x.
33. Ferrari AJ, Charlson FJ, Norman RE, et al. Burden of depressive disorders by country, sex, age, and year: findings from the global burden of disease study 2010. PLoS Med. 2013;10:e1001547.
34. Ferrari AJ, Stockings E, Khoo JP, et al. The prevalence and burden of bipolar disorder: findings from the Global Burden of Disease Study 2013. Bipolar Disord. 2016;18:440–50.
35. Flint J, Kendler KS. The genetics of major depression. Neuron. 2014;81:484–503.
36. Freund CL, Clayton EW, Wilfond BS. Natural settings trials—improving the introduction of clinical genetic tests. J Law, Med Ethics: J Am Soc Law, Med Ethics. 2004;32:106–10.
37. Garcia-Gonzalez J, Tansey KE, Hauser J, et al. Pharmacogenetics of antidepressant response: a polygenic approach. Prog Neuro-Psychopharmacol Biol Psychiatry. 2017;75:128–34.
38. Garriock HA, Kraft JB, Shyn SI, et al. A genomewide association study of citalopram response in major depressive disorder. Biol Psychiatry. 2010;67:133-8.
39. Geddes JR, Burgess S, Hawton K, et al. Long-term lithium therapy for bipolar disorder: systematic review and meta-analysis of randomized controlled trials. Am J Psychiatry. 2004;161:217–22.
40. Geoffroy PA, Curis E, Courtin C, et al. Lithium response in bipolar disorders and core clock genes expression. World J Biol Psychiatry. 2017:1–14.
41. Global Burden of Disease Study C. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease study 2013. Lancet. 2015;386:743–800.
42. Golubnitschaja O, Baban B, Boniolo G, et al. Medicine in the early twenty-first century: paradigm and anticipation—EPMA position paper 2016. EPMA J. 2016;7:23.
43. Golubnitschaja O, Costigliola V, EPMA. EPMA summit 2014 under the auspices of the presidency of Italy in the EU: professional statements. EPMA J. 2015;6:4.
44. Golubnitschaja O, Costigliola V, EPMA. General report & recommendations in predictive, preventive and personalised medicine 2012: white paper of the European Association for Predictive, Preventive and Personalised Medicine. EPMA J. 2012;3:14.
45. Golubnitschaja O, Kinkorova J, Costigliola V. Predictive, preventive and personalised medicine as the hardcore of ‘horizon 2020’: EPMA position paper. EPMA J. 2014;5:6.
46. Gratten J, Wray NR, Keller MC, et al. Large-scale genomics unveils the genetic architecture of psychiatric disorders. Nat Neurosci. 2014;17:782–90.
47. Grof P, Duffy A, Cavazzoni P, et al. Is response to prophylactic lithium a familial trait? J Clin Psychiatry. 2002;63:942–7.
48. Guilloux JP, Bassi S, Ding Y, et al. Testing the predictive value of peripheral gene expression for nonremission following citalopram treatment for major depression. Neuropsychopharmacology. 2015;40:701–10.
49. Halushka MK, Fan JB, Bentley K, et al. Patterns of single-nucleotide polymorphisms in candidate genes for blood-pressure homeostasis. Nat Genet. 1999;22:239–47.
50. Hennings JM, Owashi T, Binder EB, et al. Clinical characteristics and treatment outcome in a representative sample of depressed inpatients—findings from the Munich Antidepressant Response Signature (MARS) project. J Psychiatr Res. 2009;43:215–29.
51. Hieronymus F, Emilsson JF, Nilsson S, et al. Consistent superiority of selective serotonin reuptake inhibitors over placebo in reducing depressed mood in patients with major depression. Mol Psychiatry. 2016;21:523–30.
52. Hirschfeld RM. Efficacy of SSRIs and newer antidepressants in severe depression: comparison with TCAs. J Clin Psychiatry. 1999;60:326–35.
53. Hodgson K, Mufti SJ, Uher R, et al. Genome-wide approaches to antidepressant treatment: working towards understanding and predicting response. Genome Med. 2012;4:52.
54. Horstmann S, Lucae S, Menke A, et al. Polymorphisms in GRIK4, HTR2A, and FKBP5 show interactive effects in predicting remission to antidepressant treatment. Neuropsychopharmacology. 2010;35:727–40.
55. Hou L, Bergen SE, Akula N, et al. Genome-wide association study of 40,000 individuals identifies two novel loci associated with bipolar disorder. Hum Mol Genet. 2016;25:3383–94.
56. Hou L, Heilbronner U, Degenhardt F, et al. Genetic variants associated with response to lithium treatment in bipolar disorder: a genome-wide association study. Lancet. 2016;387:1085–93.
57. Hughes B. Novel consortium to address shortfall in innovative medicines for psychiatric disorders. Nat Rev Drug Discov. 2009;8:523–4.
58. Hunter AM, Leuchter AF, Power RA, et al. A genome-wide association study of a sustained pattern of antidepressant response. J Psychiatr Res. 2013;47:1157–65.
59. Hyde CL, Nagle MW, Tian C, et al. Identification of 15 genetic loci associated with risk of major depression in individuals of European descent. Nat Genet. 2016;48:1031–6.
60. Iniesta R, Malki K, Maier W, et al. Combining clinical variables to optimize prediction of antidepressant treatment outcomes. J Psychiatr Res. 2016;78:94–102.
61. Iniesta R, Stahl D, Mcguffin P. Machine learning, statistical learning and the future of biological research in psychiatry. Psychol Med. 2016;46:2455–65.
62. Ising M, Lucae S, Binder EB, et al. A genome-wide association study points to multiple loci predicting antidepressant treatment outcome in depression. Arch Gen Psychiatry. 2009;66:966–75.
63. Kauzna-Czapliska J, Zurawicz E, Michalska M, et al. A focus on homocysteine in autism. Acta Biochim Pol. 2013;60:137-42.
64. Kawaguchi DM, Glatt SJ. GRIK4 polymorphism and its association with antidepressant response in depressed patients: a meta-analysis. Pharmacogenomics. 2014;15:1451–9.
65. Kinkorová J. Biobanks in the era of personalized medicine: objectives, challenges, and innovation. EPMA J. 2016;7:4.
66. Kleindienst N, Engel RR, Greil W. Psychosocial and demographic factors associated with response to prophylactic lithium: a systematic review for bipolar disorders. Psychol Med. 2005;35:1685–94.
67. Korgaonkar M, Goldstein-Piekarski A, Fornito A, et al. 253. Functional connectome networks underlying outcomes of antidepressant medication in major depressive disorders. Biol Psychiatry. 2017;81:S104.
68. Lee MS, Lee HY, Lee HJ, et al. Serotonin transporter promoter gene polymorphism and long-term outcome of antidepressant treatment. Psychiatr Genet. 2004;14:111–5.
69. Lemke HU, Golubnitschaja O. Towards personal health care with model-guided medicine: long-term PPPM-related strategies and realisation opportunities within ‘horizon 2020’. EPMA J. 2014;5:8.
70. Li X, Bijur GN, Jope RS. Glycogen synthase kinase-3beta, mood stabilizers, and neuroprotection. Bipolar Disord. 2002;4:137–44.
71. Lichtenstein P, Yip BH, Björk C, et al. Common genetic determinants of schizophrenia and bipolar disorder in Swedish families: a population-based study. Lancet. 2009;373:234–9.
72. Malki K, Tosto MG, Mouriño-Talín H, et al. Highly polygenic architecture of antidepressant treatment response: comparative analysis of SSRI and NRI treatment in an animal model of depression. Am J Med Genet B Neuropsychiatr Genet. 2017;174:235–50.
73. Mamdani F, Alda M, Grof P, et al. Lithium response and genetic variation in the CREB family of genes. American journal of medical genetics. B, Neuropsychiatr Genet: Publi Int Soc Psychiatr Genet. 2008;147B:500–4.
74. Masui T, Hashimoto R, Kusumi I, et al. A possible association between the -116C/G single nucleotide polymorphism of the XBP1 gene and lithium prophylaxis in bipolar disorder. Int J Neuropsychopharmacol. 2006;9:83–8.
75. Masui T, Hashimoto R, Kusumi I, et al. A possible association between missense polymorphism of the breakpoint cluster region gene and lithium prophylaxis in bipolar disorder. Prog Neuro-Psychopharmacol Biol Psychiatry. 2008;32:204–8.
76. Matsumoto Y, Fabbri C, Pellegrini S, et al. Serotonin transporter gene: a new polymorphism may affect response to antidepressant treatments in major depressive disorder. Mol Diagn Ther. 2014;18:567–77.
77. Mcguffin P, Rijsdijk F, Andrew M, et al. The heritability of bipolar affective disorder and the genetic relationship to unipolar depression. Arch Gen Psychiatry. 2003;60:497–502.
78. Mcmahon FJ, Buervenich S, Charney D, et al. Variation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatment. Am J Hum Genet. 2006;78:804–14.
79. Menke A, Binder EB. Epigenetic alterations in depression and antidepressant treatment. Dialogues Clin Neurosci. 2014;16:395–404.
80. Merikangas KR, Jin R, He J-P, et al. Prevalence and correlates of bipolar spectrum disorder in the world mental health survey initiative. Arch Gen Psychiatry. 2011;68:241–51.
81. Min W, Li T, Ma X, et al. Monoamine transporter gene polymorphisms affect susceptibility to depression and predict antidepressant response. Psychopharmacology. 2009;205:409–17.
82. Mrazek DA. Psychiatric pharmacogenomic testing in clinical practice. Dialogues Clin Neurosci. 2010;12:69–76.
83. Mrazek DA, Biernacka JM, Mcalpine DE, et al. Treatment outcomes of depression: the pharmacogenomic research network antidepressant medication pharmacogenomic study. J Clin Psychopharmacol. 2014;34:313–7.
84. Mühleisen TW, Leber M, Schulze TG, et al. Genome-wide association study reveals two new risk loci for bipolar disorder. Nat Commun. 2014;5:3339.
85. Murray CJL, Barber RM, Foreman KJ, et al. Global, regional, and national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries, 1990–2013: quantifying the epidemiological transition. Lancet. 2015;386:2145–91.
86. Niitsu T, Fabbri C, Bentini F, et al. Pharmacogenetics in major depression: a comprehensive meta-analysis. Prog Neuro-Psychopharmacol Biol Psychiatry. 2013;45:183–94.
87. O'donovan MC, Owen MJ. The implications of the shared genetics of psychiatric disorders. Nat Med. 2016;22:1214–9.
88. Oestergaard S, Moldrup C. Anticipated outcomes from introduction of 5-HTTLPR genotyping for depressed patients: an expert Delphi analysis. Public Health Genomics. 2010;13:406–14.
89. Papakostas GI, Fava M, Thase ME. Treatment of SSRI-resistant depression: a meta-analysis comparing within- versus across-class switches. Biol Psychiatry. 2008;63:699–704.
90. Perlis RH. Cytochrome P450 genotyping and antidepressants. BMJ: Br Med J. 2007;334:759–9.
91. Peters EJ, Slager SL, Mcgrath PJ, et al. Investigation of serotonin-related genes in antidepressant response. Mol Psychiatry. 2004;9:879–89.
92. Psychiatric GCBDWG. Large-scale genome-wide association analysis of bipolar disorder identifies a new susceptibility locus near ODZ4. Nat Genet. 2011;43:977–83.
93. Purcell SM, Wray NR, Stone JL, et al. Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. Nature. 2009;460:748–52.
94. Ritchie MD, Holzinger ER, Li R, et al. Methods of integrating data to uncover genotype-phenotype interactions. Nat Rev Genet. 2015;16:85–97.
95. Rush AJ, Fava M, Wisniewski SR, et al. Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design. Control Clin Trials. 2004;25:119–42.
96. Rybakowski JK, Dmitrzak-Weglar M, Kliwicki S, et al. Polymorphism of circadian clock genes and prophylactic lithium response. Bipolar Disord. 2014;16:151–8.
97. Rybakowski JK, Dmitrzak-Weglarz M, Suwalska A, et al. Dopamine D1 receptor gene polymorphism is associated with prophylactic lithium response in bipolar disorder. Pharmacopsychiatry. 2009;42:20–2.
98. Rybakowski JK, Suwalska A, Skibinska M, et al. Prophylactic lithium response and polymorphism of the brain-derived neurotrophic factor gene. Pharmacopsychiatry. 2005;38:166–70.
99. Schulze TG, Alda M, Adli M, et al. The international consortium on lithium genetics (ConLiGen): an initiative by the NIMH and IGSLI to study the genetic basis of response to lithium treatment. Neuropsychobiology. 2010;62:72–8.
100. Serretti A, Lilli R, Lorenzi C, et al. Tryptophan hydroxylase gene and response to lithium prophylaxis in mood disorders. J Psychiatr Res. 1999;33:371–7.
101. Serretti A, Lilli R, Mandelli L, et al. Serotonin transporter gene associated with lithium prophylaxis in mood disorders. Pharmacogenomics J. 2001;1:71–7.
102. Serretti A, Malitas PN, Mandelli L, et al. Further evidence for a possible association between serotonin transporter gene and lithium prophylaxis in mood disorders. Pharmacogenomics J. 2004;4:267–73.
103. Silberberg G, Levit A, Collier D, et al. Stargazin involvement with bipolar disorder and response to lithium treatment. Pharmacogenet Genomics. 2008;18:403–12.
104. Singh AB, Baune BT, Hamilton A, et al. Psychotropic pharmacogenetics—distraction or destiny? Aust N Z J Psychiatry. 2017;51:665–7.
105. Soares JC, Gershon S. The lithium ion: a foundation for psychopharmacological specificity. Neuropsychopharmacology. 1998;19:167–82.
106. Song J, Bergen SE, Di Florio A, et al. Genome-wide association study identifies SESTD1 as a novel risk gene for lithium-responsive bipolar disorder. Mol Psychiatry. 2016;21:1290–7.
107. Spencer CCA, Su Z, Donnelly P, et al. Designing genome-wide association studies: sample size, power, imputation, and the choice of genotyping Chip. PLoS Genet. 2009;5:e1000477.
108. Steen VM, Lovlie R, Osher Y, et al. The polymorphic inositol polyphosphate 1-phosphatase gene as a candidate for pharmacogenetic prediction of lithium-responsive manic-depressive illness. Pharmacogenetics. 1998;8:259–68.
109. Sullivan PF, Neale MC, Kendler KS. Genetic epidemiology of major depression: review and meta-analysis. Am J Psychiatr. 2000;157:1552–62.
110. Szczepankiewicz A, Rybakowski JK, Suwalska A, et al. Glucocorticoid receptor polymorphism is associated with lithium response in bipolar patients. Neuro Endocrinol Lett. 2011;32:545–51.
111. Szczepankiewicz A, Skibinska M, Suwalska A, et al. The association study of three FYN polymorphisms with prophylactic lithium response in bipolar patients. Hum Psychopharmacol. 2009;24:287–91.
112. Tansey KE, Guipponi M, Hu X, et al. Contribution of common genetic variants to antidepressant response. Biol Psychiatry. 2013;73:679–82.
113. Tansey KE, Guipponi M, Perroud N, et al. Genetic predictors of response to serotonergic and noradrenergic antidepressants in major depressive disorder: a genome-wide analysis of individual-level data and a meta-analysis. PLoS Med. 2012;9:e1001326.
114. The Genomes Project C. A global reference for human genetic variation. Nature. 2015;526:68–74.
115. Thomas L, Mulligan J, Mason V, et al. GENetic and clinical predictors of treatment response in depression: the GenPod randomised trial protocol. Trials. 2008;9:29.
116. Uher R, Perroud N, Ng MY, et al. Genome-wide pharmacogenetics of antidepressant response in the GENDEP project. Am J Psychiatry. 2010;167
117. Uher R, Tansey KE, Henigsberg N, et al. Common genetic variation and antidepressant efficacy in major depressive disorder: a meta-analysis of three genome-wide pharmacogenetic studies. Am J Psychiatr. 2013;170:207–17.
118. Van Der Weide J, Hinrichs JWJ. The influence of cytochrome P450 pharmacogenetics on disposition of common antidepressant and antipsychotic medications. Clin Biochem Rev. 2006;27:17–25.
119. Vialou V, Feng J, Robison AJ, et al. Epigenetic mechanisms of depression and antidepressants action. Annu Rev Pharmacol Toxicol. 2013;53:59–87.
120. Whiteford HA, Degenhardt L, Rehm J, et al. Global burden of disease attributable to mental and substance use disorders: findings from the global burden of disease study 2010. Lancet. 2013;382:1575–86.
121. Winner J, Allen JD, Anthony Altar C, et al. Psychiatric pharmacogenomics predicts health resource utilization of outpatients with anxiety and depression. Transl Psychiatry. 2013;3:e242.